一致第一季度报告正文英文版

1、-14.46%china national accord medicines corporation ltd.stock code: 000028, 200028the first quarterly report for 2012notice no.: 2012-08short form of the stock: sinopharm accord, accord-bchina national accord medicines corporation ltd.the first quarterly report 20121. important notes1.1 board of dire

2、ctors and the supervisory committee of china national accord medicinescorporation ltd. (hereinafter referred to as the company) and its directors, supervisors and seniorexecutives hereby confirm that there are no any fictitious statements, misleading statements, orimportant omissions carried in this

3、 report, and shall take all responsibilities, individual and/or joint,for the reality, accuracy and completion of the whole contents.1.2 the first quarterly financial report of 2012 has not been audited by cpas.1.3 mr. wei yulin, chairman of the company; mr. yan zhigang, director general manager; mr

4、.wei pingxiao, cfo and mr. chi guoguang, financial manager hereby confirm that the financialreport of the first quarterly report is true and complete.2. company profile2.1 main accounting highlights and financial indexesunit: rmbat the end of thereport periodat the period-end of the last yearchanges

5、 ofbeforeafter adjustment increase/decrease (%)adjustmenttotal assets (rmb)8,069,831,512.29 7,665,759,761.04 7,680,629,146.675.07%ownersequityattributabletoshareholders of the listed company(rmb)total share capital (share)1,467,647,406.10288,149,400.001,350,217,871.35288,149,400.001,350,093,276.8628

6、8,149,400.008.71%0.00%net asset per share attributable toshareholders of listed company5.0934.6864.6858.71%(rmb/share)in the report periodthe same period of last yearchanges ofbeforeafter adjustment increase/decrease (%)adjustmenttotal operating income (rmb)4,274,691,013.50 3,526,818,451.42 3,534,42

7、6,881.4720.94%net profit attributable to shareholders ofthe listed company (rmb)121,822,129.2487,259,288.1787,197,481.0239.71%net cash flow arising from operatingactivities (rmb)-271,437,536.92 -316,947,045.11 -317,332,260.53net cash flow arising from operatingactivities per share (rmb/share)basic e

8、arnings per share (rmb/share)diluted earnings per share (rmb/share)weighted average return on equity (%)-0.9420.4230.4238.63%-1.1000.3030.3037.96%-1.1010.3030.3037.94%-14.44%39.60%39.60%0.69%weighted average return on equity afterdeducting non-recurring gains and8.58%7.70%7.69%0.89%losses (%)items o

9、f non-recurring gains and losses applicable inapplicableunit: rmb1-china national accord medicines corporation ltd.the first quarterly report for 2012items of non-recurring gains and lossesgains and losses from the disposal of non-current assetsgovernmental subsidy reckoned into current gains and lo

10、sses,but closely relevant to the companys business except for thegovernmental subsidy enjoyed in quota or ration according tothe national general standardscurrent net gains/losses of subsidiary generated fromperiod-begin to consolidation date by enterprise merger undersame controlimpairment provisio

11、n reversal on account receivable whichconducting impairment testing separatelyother non-operating income and expenditure except for theabove itemsinfluenced amount of minority shareholders equityinfluenced amount of income taxtotalamount fromyear-begin toperiod-end-35,049.591,284,500.28-175,050.3624

12、2,309.84199,552.20-440,050.00-268,622.84807,589.53remarks (ifapplicable)2.2 total number of shareholders at the end of the report period and shares held by the topten shareholders with unrestricted conditionsunit: sharetotal number of shareholdersat the end of report period18,481particulars about th

13、e shares held by the top ten tradable shareholders with unrestricted conditionsamount of tradable shares withfull name of shareholdersinopharm group co., ltd.icbcguangfa jufengstock fundicbcharvest theme newpower stock fundhthk/cmg fsgufp-cmg firststate china growth fdabcgreatwal anxinreturn mex sto

14、ck fundicbcharvest strategygrowth mixed stock fundabcjinshun greatwallresources monopolystock fund (lof)icbc- gd strategyselected mixed stockfundicbc universal balancegworth stock fundccbgreatwall consumervalue-added stock fundunrestricted conditions held atthe end of report period110,459,74813,285,

15、47710,290,2927,032,7207,000,0004,256,0424,001,4813,996,4863,721,2913,292,879type of sharesrmb common sharermb common sharermb common sharedomestically listed foreignsharermb common sharermb common sharermb common sharermb common sharermb common sharermb common share2china national accord medicines c

16、orporation ltd.the first quarterly report for 20123. significant events3.1 particulars about material changes in items of main accounting statement and financialindex, and explanations of reasonsapplicableinapplicable1. account paid in advance at period-end increase 48.18 million yuan over that of p

17、eriod-begin withrate of 73.15 percent up. mainly because the projects and equipment amount paid in advanceincreased from zhijun pharmaceutical, subsidiary of the company; meanwhile, amount paid for goodpurchasing in advance increased due to soaring sales.2. other account receivable at period-end inc

18、rease 10.59 million yuan over that of period-begin withrate of 36.96 percent up. mainly because acquisition of subsidiary sinopharm zhaoqing in this periodand amount of office establishment of sinopharm guangxi, subsidiary of the company pre-paid.3. other current assets at period-end decrease 5.16 m

19、illion yuan over that of period-begin with rate of-67.44 percent up. mainly because excess payable vat and income tax decreased.4. account paid in advance at period-end increase 29.61 million yuan over that of period-begin withrate of 50.44 percent up. mainly because zhijun pharmaceutical, subsidiar

20、y of the company, showsfavorable condition in aspect of sales, amount for goods received in advance increased.5. wages payable at period-end decrease 43.8 million yuan over that of period-begin with rate of-30.75 percent up. mainly because some of the remuneration, accrual last year, have been paid

21、in thisperiod.6. taxes payable at period-end increase 28.09 million yuan over that of period-begin with rate of44.17 percent up. mainly because vary taxes growth due to soaring sales and higher profitability.7. long-term loans at period-end increase 37.12 million yuan over that of period-begin with

22、rate of39.88 percent up. mainly because the new loans for sinopharm guangxi logistic park project,subsidiary of the company, and phase ii, guanlan, medicine r & d base of zhijun pharmaceutical,subsidiary of the company.8. capital reserve at period-end decrease 3.06 million yuan over that of peri

23、od-begin with rate of-35.52 percent up. mainly because sinopharm wuzhou company was merged by the company undersame control, the make a retroactive adjustment on amount at year-begin.9. financial expense has a y-o-y growth of 19.29 million yuan with 73.78 percent up. mainly becauseon one hand, lendi

24、ng rates growth affected by monetary tightening policy of the state; on the otherhand, financing cost increased due to financing scale enlarged.10. loss of assets impairment has a y-o-y decrease of 5.17 million yuan with -95.92 percent up.mainly because strictly control in inventory management and r

25、apid up turnover of the inventory, anddepreciation provision for inventory accrued decreased.11. non-operating income has a y-o-y decline of 0.95 million yuan with -33.57 percent up. mainlybecause government subsidy obtained in this period decreased over same period of last year.12. non-operating ex

26、penses have a y-o-y growth of 0.4 million yuan with 1,097.66 percent up.mainly because external donation and losses from disposal of non-current assets show an increaseover same period of last year.13. net profit has a y-o-y growth of 33.91 million yuan with 38.14 percent up. mainly because salessca

27、le enlarged, and by controlling reasonable expenses and adjusted products structure forsubordinate subsidiaries of the company, profitability gains a more room for growth.14. minority interest income has a y-o-y decline of 0.72 million yuan with -42.30 percent up. mainlybecause zhijun wanqing, subsi

28、diary of the company, has a lower net profit than same period of lastyear.15. taxes returned received have a y-o-y growth of 90,000 yuan with 116.38 percent up. mainlybecause zhijun medicine trade company, subsidiary of the company, has a higher export return taxthan same period of last year.16. oth

29、er cash received from operating activities have a y-o-y decline of 10.45 million yuan with-36.99 percent up. mainly because government subsidy and other items obtained in this period have3china national accord medicines corporation ltd.the first quarterly report for 2012lower amount than same period

30、 of last year.17. net cash received from disposal of fixed assets, intangible assets and other long-term assets havea y-o-y decline of 0.3 million yuan with -58.85 percent up. mainly because zhijun pharmaceutical,subsidiary of the company, disposed some of the vehicle at same period of last year whi

31、le no suchbusiness occurred in this period.18. other cash received from investment activities have a y-o-y decline of 1.91 million yuan with-100 percent up. mainly because sinopharm guangxi logistic, subsidiary of the company, obtainedsupporting grant for logistic projects from nanning economy devel

32、opment zone at same period oflast year while no such business occurred in this period.19. acquisition of subsidiaries and other business units，net cash have a y-o-y growth of 5.09 millionyuan with 100 percent up. mainly because sinopharm zhaoqing and sinopharm wuzhou wereacquired by the company in t

33、his period whiles no such business occurred at same period of last year.20. other cash paid for investment activities have a y-o-y decline of 9.7 million yuan with -100percent up. mainly because sinopharm guangxi paid balance of business acquisition of nanningmedicine at same period of last year whi

34、le no such business occurred in this period.21. other cash received from financing activities have a y-o-y growth of 326.42 million yuan with1,732.72 percent up. mainly because entrusted loans were increased and application of financinginstrument of supplying chains for purpose of supporting busines

35、s development.22. cash paid for debt settlement have a y-o-y growth of 108.73 million yuan with 105.60 percent up.mainly because loans growth that debt payment correspondingly increased.23. cash paid for dividend and profit distribution or interest settlement have a y-o-y growth of 18.36million yuan

36、 with 97.12 percent up. mainly because financing cost increased due to financing scaleenlarged.24. other cash paid for financing activities have a y-o-y growth of 284.62 million yuan with 869.66percent up. mainly because entrusted loans were paid in this period and financing from supplyingchains inc

37、reased over same period of last year.25. influence on cash and cash equivalent from exchange rate movement has a y-o-y decline of 2,800yuan with -1,528.95 percent up. mainly because of the amount of foreign currency held increased.3.2 analysis and explanation of significant events and their influenc

38、e and solutions3.2.1 particular about qualified opinionapplicableinapplicable3.2.2 particular about fund offered to shareholder or its related parties by the company andexternal guarantee with procedure violationapplicableinapplicable3.2.3 particular about the significant contract of routine operati

39、on signed and implementedapplicable3.2.4 otherapplicableinapplicableinapplicablethe company purchased sinopharm wuzhou co., ltd. under same control in march 2012, madeadjustment on comparison statements dated march 2011 in line with relevant regulations ofaccounting standards for business enterprises no. 20 business combination. income fromjanuary to march for year o